Zheng Quan Shi Bao Wang·2025-09-22 00:36Company Overview - The company, Xianwei Bio, has submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CICC serving as joint sponsors [1] - The company focuses on addressing medical needs in the weight management sector and plans to launch its core product, Enoglutide Injection (XW003), in China [1] Product Details - Enoglutide Injection is expected to be the world's first cAMP-biased GLP-1 receptor agonist for the treatment of overweight/obesity and type 2 diabetes [1] - Clinical data indicates that Enoglutide Injection demonstrates superior weight loss effects in Chinese patients with overweight/obesity compared to Semaglutide, achieving the efficacy of Tirzepatide at a lower dosage [1] Market Potential - The global weight management drug market is substantial and steadily growing, projected to expand to $165.9 billion by 2029 [1] - The global market for overweight/obesity drugs is expected to show strong growth potential, with an estimated market size of $41.7 billion by 2029 and a compound annual growth rate (CAGR) of 19.8% [1]